These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 12476790

  • 1. Molecular basis of hyperparathyroidism and potential targets for drug development.
    Krebs LJ, Arnold A.
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):167-79. PubMed ID: 12476790
    [Abstract] [Full Text] [Related]

  • 2. Molecular pathogenesis of primary hyperparathyroidism.
    Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y, Saucier K.
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
    [Abstract] [Full Text] [Related]

  • 3. Molecular genetics of primary and secondary hyperparathyroidism.
    Dotzenrath C, Goretzki PE, Farnebo F, Teh BT, Weber G, Röher HD, Larsson C.
    Exp Clin Endocrinol Diabetes; 1996 Nov; 104 Suppl 4():105-7. PubMed ID: 8981014
    [Abstract] [Full Text] [Related]

  • 4. Molecular pathogenesis of primary hyperparathyroidism.
    Cetani F, Pardi E, Borsari S, Marcocci C.
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
    [Abstract] [Full Text] [Related]

  • 5. Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism.
    McCann LM, Beto J.
    J Ren Nutr; 2010 May; 20(3):141-50. PubMed ID: 20303786
    [Abstract] [Full Text] [Related]

  • 6. The genetic background of uremic secondary hyperparathyroidism.
    Aucella F, Morrone L, Stallone C, Gesualdo L.
    J Nephrol; 2005 May; 18(5):537-47. PubMed ID: 16299679
    [Abstract] [Full Text] [Related]

  • 7. Parathyroid surgery in familial hyperparathyroid disorders.
    Carling T, Udelsman R.
    J Intern Med; 2005 Jan; 257(1):27-37. PubMed ID: 15606374
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1.
    Carling T, Kindmark A, Hellman P, Holmberg L, Akerström G, Rastad J.
    Biochem Biophys Res Commun; 1997 Feb 13; 231(2):329-32. PubMed ID: 9070272
    [Abstract] [Full Text] [Related]

  • 9. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
    Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K.
    Clin Endocrinol (Oxf); 2006 Jul 13; 65(1):9-16. PubMed ID: 16817812
    [Abstract] [Full Text] [Related]

  • 10. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
    Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2005 Aug 13; 9 Suppl 1():S27-34. PubMed ID: 16109139
    [Abstract] [Full Text] [Related]

  • 11. [Primary hyperparathyroidism is common among postmenopausal women. Identification of genetic risk factors can contribute to individualized treatment].
    Correa P, Szabo E, Lundgren E, Carling T.
    Lakartidningen; 2001 May 02; 98(18):2198-200. PubMed ID: 11402599
    [Abstract] [Full Text] [Related]

  • 12. Calcimimetics and hyperparathyroidism.
    Krebs LJ.
    Curr Opin Investig Drugs; 2004 Oct 02; 5(10):1080-5. PubMed ID: 15535429
    [Abstract] [Full Text] [Related]

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 02; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 14. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
    Bas S, Aguilera-Tejero E, Bas A, Estepa JC, Lopez I, Madueño JA, Rodriguez M.
    J Endocrinol; 2005 Jan 02; 184(1):241-7. PubMed ID: 15642800
    [Abstract] [Full Text] [Related]

  • 15. [Concept, etiology and epidemiology of primary hyperparathyroidism].
    Martínez Díaz-Guerra G, Hawkins Carranza F.
    Endocrinol Nutr; 2009 Apr 02; 56 Suppl 1():2-7. PubMed ID: 19627754
    [Abstract] [Full Text] [Related]

  • 16. Molecular biology of primary hyperparathyroidism.
    Ferris RL, Simental AA.
    Otolaryngol Clin North Am; 2004 Aug 02; 37(4):819-31, x. PubMed ID: 15262518
    [Abstract] [Full Text] [Related]

  • 17. Molecular pathology of parathyroid tumors.
    Carling T.
    Trends Endocrinol Metab; 2001 Mar 02; 12(2):53-8. PubMed ID: 11167122
    [Abstract] [Full Text] [Related]

  • 18. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism.
    Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A.
    Mol Endocrinol; 2005 Oct 02; 19(10):2603-9. PubMed ID: 15928311
    [Abstract] [Full Text] [Related]

  • 19. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management.
    Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L, Vignali E, Viacava P, Berti P, Mariotti S, Pinchera A, Marcocci C.
    Clin Endocrinol (Oxf); 2006 Feb 02; 64(2):146-52. PubMed ID: 16430712
    [Abstract] [Full Text] [Related]

  • 20. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.
    Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A.
    J Clin Invest; 2001 May 02; 107(9):1093-102. PubMed ID: 11342573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.